Patent: 10,011,660
✉ Email this page to a colleague
Summary for Patent: 10,011,660
Title: | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
Abstract: | Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide. |
Inventor(s): | Tsui; Ping (Gaithersburg, MD), Borrok, II; Martin (Gaithersburg, MD), Dall\'Acqua; William (Gaithersburg, MD) |
Assignee: | MedImmune, LLC (Gaithersburg, MD) |
Application Number: | 14/397,958 |
Patent Claims: | see list of patent claims |
Details for Patent 10,011,660
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Csl Behring Ag | CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN | immune globulin intravenous (human) | For Injection | 102367 | 07/27/2000 | ⤷ Try a Trial | 2032-04-30 |
Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | 07/26/2007 | ⤷ Try a Trial | 2032-04-30 |
Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | 10/02/2009 | ⤷ Try a Trial | 2032-04-30 |
Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | 02/07/2013 | ⤷ Try a Trial | 2032-04-30 |
Bio Products Laboratory | GAMMAPLEX | immune globulin intravenous (human) | Injection | 125329 | 09/17/2009 | ⤷ Try a Trial | 2032-04-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |